Equities

Ind Swift Ltd

INDSWFTLTD:NSI

Ind Swift Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)23.60
  • Today's Change-0.300 / -1.26%
  • Shares traded26.31k
  • 1 Year change+5.59%
  • Beta0.8133
Data delayed at least 15 minutes, as of Sep 20 2024 11:18 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Ind Swift Ltd had net income fall -45.34% from 260.37m to 142.31m despite a 22.21% increase in revenues from 4.11bn to 5.02bn. An increase in the cost of goods sold as a percentage of sales from 53.06% to 55.98% was a component in the falling net income despite rising revenues.
Gross margin45.63%
Net profit margin8.58%
Operating margin1.62%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, Ind Swift Ltd increased its cash reserves by 373.72%, or 498.09m. Cash Flow from Investing totalled 766.07m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 152.83m in cash from operations while cash used for financing totalled 420.81m.
Cash flow per share12.17
Price/Cash flow per share1.94
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Ind Swift Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.